UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1294-6
Program Prior Authorization/Notification
Medication Inrebic® (fedratinib)
P&T Approval Date 10/2019, 10/2020, 10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Inrebic (fedratinib) is a kinase inhibitor indicated for the treatment of adult patients with
intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential
thrombocythemia) myelofibrosis (MF).
The National Cancer Comprehensive Network (NCCN) also recommends Inrebic for the
treatment of myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangement.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age
of 19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Inrebic will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Myelofibrosis
1. Initial Authorization
a. Inrebic will be approved based on the following diagnoses:
(1) Diagnosis of intermediate-2 or high-risk primary or secondary (post-
polycythemia vera or post-essential thrombocythemia) myelofibrosis
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
1
2. Reauthorization
a. Inrebic will be approved based on the following criterion:
(1) Documentation that patient has evidence of symptom improvement or
reduction in spleen volume while on Inrebic
Authorization will be issued for 12 months.
C. Myeloid/Lymphoid Neoplasms
1. Initial Authorization
a. Inrebic will be approved based on both of the following:
(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with
eosinophilia
-AND-
(2) Patient has a JAK2 rearrangement
Authorization will be issued for 12 months.
2. Reauthorization
a. Inrebic will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Inrebic therapy.
Authorization will be issued for 12 months.
D. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Inrebic [package insert]. Summit, NJ: Celgene Corporation. July 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
https://www.nccn.org/professionals/drug_compendium/content/ Accessed September 4, 2024
Program Prior Authorization/Notification – Inrebic® (fedratinib)
Change Control
10/2019 New program.
10/2020 Annual review. Updated background and coverage criteria to include
NCCN recommended use in myeloid/lymphoid neoplasms. Updated
references.
10/2021 Annual review with no change to clinical coverage criteria.
10/2022 Annual review. Updated myelofibrosis criteria to labeled indication.
Updated references. Added state mandate footnote.
10/2023 Annual review with no change to clinical coverage criteria. Updated
references.
10/2024 Annual review with no change to clinical coverage criteria. Updated
references.
© 2024 UnitedHealthcare Services, Inc.
3